Mesenchymal Stem Cell Selection for Immune Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immune-related diseases, such as arthritis, rely on nonsteroidal anti-inflammatory drugs and immunosuppressants, which provide temporary relief but come with significant side effects and do not cure the diseases, necessitating a safer and more effective treatment method.
Innovation Solution
A method involving the identification and use of mesenchymal stem cells (MSCs) exposed to IFN-γ, characterized by an immunosuppressive protein binding value (IPBv) greater than 170 towards indoleamine 2,3-dioxygenase (IDO), which are then administered to alleviate immune responses and treat immune-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonsteroidal anti-inflammatory drugs and immunosuppressants are used to treat immune-related diseases, then temporary relief of symptoms is achieved, but significant side effects occur and the diseases are not cured
Solution Approach 1:
The patent changes the fundamental parameter of treatment from chemical drugs to biological cells (mesenchymal stem cells). The MSCs are characterized by specific parameters including IPBv > 170 toward IDO and CD105 positivity, which enables them to provide curative treatment without the harmful side effects of conventional drugs. This parameter change represents a paradigm shift from pharmacological intervention to cellular therapy.
Solution Approach 2:
The patent uses mesenchymal stem cells as intermediary agents between the patient's immune system and the disease target. The MSCs act as mediators that modulate immune responses through contact-dependent and contact-independent mechanisms, including the expression of immunosuppressive proteins like IDO, thereby achieving therapeutic effect without direct toxic action on the patient's body.
2Reliability
If conventional drugs are administered to alleviate symptoms, then temporary improvement is achieved, but the diseases progress without cure
Solution Approach 1:
The patent performs preliminary characterization and selection of mesenchymal stem cells before administration to ensure they possess the necessary therapeutic properties. The cells are pre-screened for IPBv > 170 toward IDO and CD105 positivity, which ensures that when administered, they will provide sustained curative effect rather than temporary relief. This preliminary selection action guarantees long-term therapeutic durability.
Solution Approach 2:
The patent establishes continuous useful action through the long-term persistence and functional activity of mesenchymal stem cells in the patient's body. Unlike drugs that are metabolized and eliminated, the MSCs can persist, differentiate, and continuously modulate immune responses over extended periods, providing durable curative effect rather than temporary symptom relief.
3Object-affected harmful factors
If immunosuppressants are used to control immune response, then inflammation is reduced, but infection risk and other adverse effects increase
Solution Approach 1:
The patent applies local quality by having mesenchymal stem cells express immunosuppressive proteins (such as IDO with IPBv > 170) specifically at the site of disease activity rather than systemically suppressing the immune system. This localized immunomodulation controls inflammation where needed while preserving overall immune function and reducing infection risk, as the immunosuppressive effect is confined to the therapeutic site rather than being globally applied.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The identified MSCs effectively inhibit immune responses, ameliorating symptoms associated with immune-related diseases like arthritis, improving knee function and pain scores in patients, with the IPBv serving as a biomarker for therapeutic efficacy.
Implementation Method 1
determining an immunosuppressive protein binding value (IPBv) of the plurality of MSCs toward indoleamine 2,3-dioxygenase (IDO)
Implementation Method 2
exposing the plurality of MSCs to IFN-γ at the dose of 50-800 U/ml
Data Source
AI summary
Disclosed herein is a method of identifying a plurality of mesenchymal stem cells (MSCs) that are therapeutic to a subject having an immune-related disease, for example, arthritis. According to embodiments of the present disclosure, the MSCs exhibiting to the immune-related disease are characterized in having an immunosuppressive protein binding value (IPBv) greater than 170 toward indoleamine 2,3-dioxygenase (IDO) after being exposed to 50-800 U/ml of IFN-γ. Also disclosed herein are uses of the identified MSCs for the manufacture of a medicament, and methods of treating an immune-related disease by use of the identified MSCs or medicament.